Product Pipeline

Abbreviations: GAD, generalized anxiety disorder; MDD, major depressive disorder.

*Dartmouth transaction is with a researcher employed by Dartmouth. Pear has
no direct contractual relationship with Dartmouth relating to this content.
^†Karolinska transaction is with individual researchers who are employed by the
Karolinska Institute. Pear has no direct contractual relationship with the
Karolinkska Institute relating to this content.
^‡Services agreement with Ironwood to evaluate a PDT in gastrointestinal diseases.

1. Candidates (identified as Pear-xxx) are under development at Pear and have not been evaluated for safety or effectiveness by the U.S. Food and Drug Administration. The development process is uncertain and these candidates may not become commercial products in the future. Discovery is the concept stage before clinical development, in which the product candidate, its mechanism(s) of action and target patient population(s) are defined, technical capabilities and prototypes are built, and then the candidate concept is rapidly tested in iterative evaluations.


2. Discovery is the concept stage before clinical development, in which the product candidate, its mechanism(s) of action and target patient population(s) are defined, technical capabilities and prototypes are built, and then the candidate concept is rapidly tested in iterative evaluations.


3. Proof of Concept is the early clinical development stage, in which the product candidate is being tested in human clinical trials designed to prove that the candidate concept is worthy of advancement to the Pivotal stage. POC stage activities are related to technical work, study design, planning, other operational clinical trial activities, and statistical analysis.


4. Pivotal is the registrational phase, in which the product candidate is tested in a randomized controlled trial designed to support market authorization from a regulatory authority such as FDA. Pivotal stage activities are related to technical work, study design, planning, other operational clinical trial activities, and/or statistical analysis that are part of a regulatory submission.